The present invention relates to medical methods for treating lung tumors, and more specifically to minimally invasive medical methods for ablating lung tumors.
Bronchoscopic radio frequency ablation and bronchoscopic thermal vapor ablation are examples of minimally invasive techniques to treat lung tumors in a patient.
Bronchoscopic radio frequency ablation involves navigating an ablation catheter through the airways of the patient and to the lung tumor. The ablation catheter is activated, delivering radio frequency energy to the tumor. The physician targets or focuses the energy towards the center of the tumor to minimize damage to healthy tissue adjacent the tumor.
A drawback of radio frequency ablation is that targeting the center of the lung tumor risks allowing the margin of the tumor to remain untreated. This is undesirable.
Increasing the energy delivered to the tumor, however, is also undesirable due to the likelihood of overheating the healthy tissue adjacent the tumor.
Another drawback of bronchoscopic radio frequency ablation arises from the structural limitations of the ablation electrodes and the available spacing to maneuver the electrodes. To compensate, the physician may elect to increase the energy delivered to the target. Increasing the energy delivered to the target tissue, however, risks causing collateral damage to healthy adjacent tissue.
Bronchoscopic thermal vapor ablation is another technique to treat lung tumors. Bronchoscopic thermal ablation sends a condensable vapor across the lung tumor. The vapor, upon contact with tissue, changes phase from gas to liquid, heating the outside of the lung tumor and ultimately serving to ablate the tumor. Bronchoscopic thermal vapor ablation heats the tumor from the outside to the inside. A challenge with bronchoscopic thermal vapor ablation is to quickly reach the center or inside of the lung tumor. Increasing the thermal energy delivered via the vapor is undesirable for risking collateral damage to healthy adjacent tissue.
Notwithstanding the above, minimally invasive methods and systems are still desired that effectively ablate lung tumors in a patient, and to do so without damaging the healthy adjacent tissue and without putting the patient at any further risk of infection. Accordingly, a method that overcomes the above mentioned challenges is desirable.
The present invention is a method for treating a suspect tissue mass such as, for example, a lung tumor or metastasis.
A minimally invasive medical technique for treating lung tumors includes use of multiple ablation modalities in a single procedure. Condensable vapor ablation and electrosurgical ablation are applied to treat the surface of the tumor and to debulk inner regions of the tumor, respectively.
In embodiments, a method of treating a suspect tissue mass in a lung comprises uniformly applying heat to the margin or exterior of the suspect tissue mass and discretely applying heat to interior portions of the suspect tissue mass.
In embodiments, the step of uniformly applying heat to the margin of the suspect tissue mass comprises delivering a condensable vapor around the suspect tissue mass.
In embodiments, the step of discretely applying heat to the interior of the suspect tissue mass comprises advancing an electrosurgical instrument into direct contact with the suspect tissue mass, and activating the instrument.
In embodiments, the step of discretely applying heat to the interior of the suspect tissue mass comprises placing a heat source at a discrete internal location (e.g., the center of the suspect tissue mass), and radiating heat from the heat source towards the exterior of the mass.
In embodiments, the electrosurgical instrument is an RF energy catheter.
In embodiments, the method further comprises assessing an exterior of the suspect tissue mass for uniformity prior to the step of heating by the first modality, and assessing an interior of the suspect tissue mass for density prior to the step of heating by the second modality. The steps of assessing may be performed preoperatively using CT or other imaging data, and analysis. Additionally, the step of assessing may be performed using ultrasound, bronchoscope or other diagnostic and imaging techniques. Should the suspect tissue mass be non-uniform or lack symmetry, heating is performed by delivering condensable vapor. The second modality is then carried out to heat from the inside out. In embodiments, the method further comprises monitoring a first ablation region growing inward and a second ablation region growing outward arising from the first modality and second modality of heating, respectively, and confirming an overlap zone between the first ablation region and second ablation region.
Still other descriptions, objects and advantages of the present invention will become apparent from the detailed description to follow, together with the accompanying drawings.
Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.
Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.
All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail).
Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
Method Overview
An overview of a lung tumor treatment method 10 in accordance with embodiments of the present invention is illustrated in
Step 12 states to identify a lung tumor or suspect tissue mass in the lung of the patient. By “suspect tissue mass”, it is meant a tissue mass whether diseased or otherwise a candidate for diagnosis, treatment or removal. Examples of a suspect tissue mass include, without limitation, a tumor, metastasis, growth, lymph node, tissue nodule, or other diseased tissue causing obstructions in the lung. Also, by “diseased lung tissue” it is meant a disorder or function in the lung tissue including, without limitation, emphysema, lung cancer or metastasis, TB, aspergillus, and pneumonia.
Physicians may identify the suspect tissue mass using imaging technology including, for example, CT scans, fluoroscopy, X-rays, and bronchoscopy.
Step 14 states to plan a route to the target tissue, e.g., the lung tumor. Though a physician may plan a route to the tumor by eye using the X-ray or video images of the lung and tumor, more sophisticated techniques automatically compute an optimal route to the target through the airways. Examples of airways include the trachea, bronchi, bronchial branches including, without limitation, the bronchioles and terminal bronchioles. Examples of route planning techniques are described in U.S. Pat. No. 9,037,215.
The next step shown in
Step 16 states to apply a first treatment modality to ablate the tissue margin. The first treatment modality serves to ablate across the exterior surface of the lung tumor. As will be described further herein, an exemplary first modality treatment for ablating the tumor margin includes, without limitation, condensable vapor ablation. By “margin of the tumor” it is meant the outer region or boundary of the tumor. Examples of the margin of the tumor include the outer limits, boundary, outside, and periphery of the tumor.
Step 18 states to apply a second treatment modality to debulk target tissue. As will described further herein, an instrument is advanced along the route to the target tissue. Once the position of the working tip is confirmed, energy is applied to debulk the lung tumor. Exemplary techniques to debulk the lung tumor include, without limitation, electro-surgery, microwave ablation, and cryosurgery.
With reference to
Bronchoscopic Condensable Vapor Ablation
Vapor ablation catheter 200 is shown advanced through the bronchoscope 100 and into the bronchi branch upstream or proximal to the lung tumor 400. Balloon 202 is inflated to isolate the target airways and tumor.
With reference to
An advantage of vapor ablation is that a wide range of tissue geometries may be treated because of the gaseous nature of the vapor. The catheter is not required to contact the target tissue. The vapor crosses any gaps present in the tissue until the tumor is completely engulfed or encapsulated by the vapor. Additionally, porous tissues near the tumor margin can be permeated by the vapor, and ablated.
The energy delivery or vapor ablation catheter 200 may have various configurations. Examples of vapor ablation catheters, energy generators and controllers are described in U.S. Pat. Nos. 7,913,698; 8,585,645, and US Patent Publication No. 2016/0151103. In some embodiments, the catheter is adapted to detachably couple to an energy generator (not shown).
Electrosurgical Ablation
As stated above, embodiments of the invention include treatment of a lung tumor with a second treatment modality such as, for example, radio frequency ablation. With reference to
Once the physician confirms the catheter tip 300 or RF electrode is properly positioned, the radio frequency catheter is activated. Position confirmation or tracking of the catheters can be performed by a wide range of guidance and location techniques including, without limitation, fluoroscopy or use of electromagnetic sensors. Examples of tracking and guidance techniques are described in U.S. Pat. Nos. 6,380,732 and 9,265,468 and US Patent Publication no. 2016/0180529.
In embodiments, and with reference to
An advantage of RF ablation is that the central denser portion of the tumor can be efficiently ablated. This is particularly useful for larger tumors where the heat from the vapor ablation, described above, may take longer to reach the dense central portions of the tumor. RF ablation is effective to ablate dense tissues and to debulk large volumes of tissue compared to other modalities. In contrast, condensable vapor ablation is effective to ablate across an entire surface where the geometry of the surface may be non-uniform and less dense than the central portions of the tumor.
The radio frequency energy delivery catheter may take a wide range of configurations and the electrode shape itself may also vary widely. Examples of electrode shapes include, without limitation, needle, hook, basket, loop, helix, coil, forceps or clamp, tubular, and snare or lasso. The electrode distal section may also be configured to flex, turn, and steer using mechanical or thermal action. Examples of RF ablation catheters, energy generators, and controllers are described in U.S. Pat. Nos. 6,692,494; 7,022,088 and US Patent Publication No. 2013/0046296.
Additional modalities to abate the tumor may include catheters and probes configured to deliver microwave energy, cryo-energy, or other types of energy suited to ablate lung tumors.
Similar to the method described above, step 510 states to identify the tumor in the lung of a patient. Step 510 may be performed as described above.
Step 520 queries whether the target is within an airway. If yes, the procedure may proceed substantially as outlined above in connection with the methods described above.
Particularly, step 530 states to plan the bronchoscopic route to the target tissue.
Step 540 states to advance the bronchoscope to a position along the airway in the vicinity of the target tissue, preferably with a clear view of the target to be ablated.
Step 550 states to advance the vapor ablation catheter through the bronchoscope and into position at the target tissue. The position of the catheter may be confirmed as described above.
Step 560 states to deliver condensable vapor to the exterior of the target tissue to ablate the target tissue. After treatment with the vapor, the vapor catheter is withdrawn from the patient.
Step 570 states to advance the electrosurgical ablation catheter through the bronchoscope and into contact with the target tissue. Position of the catheter may be confirmed as described above.
Step 580 states to activate the electrosurgical ablation catheter to ablate the target tissue. After ablation, the catheter is retracted from the patient.
Step 590 states to confirm target tissue ablation. The physician may monitor and confirm ablation of the tumor in real time using the bronchoscope, sensors including electrodes and thermocouples, or other imaging techniques. Ablation duration, tissue temperature, energy delivered, may also be monitored and the procedure may be terminated when a threshold level is attained.
Tumor Outside the Airway—Create Access Channel
With reference again to step 520, in the event the target is determined to be outside of the airway (e.g., in the parenchymal lung tissue), method 500 proceeds to step 522.
Step 522 states to plan the bronchoscopic route to an exit or egress opening along the airway and in the vicinity of the target tissue, and to plan a route extension from the egress opening to the target tissue.
In embodiments, planning an exit or egress opening from the airway and to the target tissue outside of the airway is performed based on a number of constraints. Examples of constraints include, without limitation, proximity to the target tissue, avoiding obstacles such as blood vessels, and physical limitations of the instruments to be used during the procedure such as size, flexibility, and bend constraints. Exemplary techniques to plan the route are descried in U.S. Pat. Nos. 8,709,034 and 9,037,215.
Step 524 states to advance the bronchoscope to a position along the airway in the vicinity of the candidate exit opening.
Step 526 states to create an access pathway to the target tissue. Particularly, step 526 states to create the opening through the airway wall, and tunnel to the tumor to create an access passage along the pre-planned route extension.
In an embodiment, the egress hole is created with a catheter fed through the bronchoscope having a sharp tip. An example of a needle catheter suitable to create the hole is described in U.S. Pat. No. 8,517,955.
In an embodiment, the hole is dilated. Openings may be enlarged using, for example, enlargeable members (e.g., balloon) or fixed tapered dilators.
An elongate tube is advanced through the hole and to the tumor. The tube may be advanced over a wire or needle, or the tube may be navigated to the tumor. In embodiments, the tube includes a removable obturator to prohibit the tube from becoming filled with tissue as the tube is advanced through the tissue.
Once the tube is in position, and the position is confirmed, the intermediate instruments such as an obturator, dilator, guidewire, or needles are retracted leaving an open channel through the tube. Position confirmation, or tracking, of the instruments for accessing the tumor can be performed by a wide range of guidance and location techniques including, without limitation, fluoroscopy or use of electromagnetic sensors. Examples of tracking and guidance techniques are described in U.S. Pat. Nos. 6,380,732 and 9,265,468 and US Patent Publication no. 2016/0180529.
Although a route extension has been described above, various techniques to create and install an access passageway to the tumor are described in the following patent publications including, without limitation, U.S. Pat. Nos. 8,784,400 and 8,709,034. See also, Anciano et al., Going Off Road The First Case Reports of the Use of the Transbronchial Access Tool With Electromagnetic Navigational Bronchoscopy, J Bronchol Intervent Pulmonol, Vol. 24, No. 3, July 2017.
Once the access passageway is installed (such as, e.g., the sheath 302 shown in
Therapeutic Agent Delivery Via Microspheres
Particularly, a number of particles or microspheres 612 are shown implanted in the vicinity of the tumor 620 and a condensable vapor 600 is delivered from the end of the catheter 610 into the target region.
The microspheres are adapted to temporarily hold and deliver a therapeutic agent to the tumor. The microspheres may be preloaded with the agent, and then implanted in the lung. The position of the microspheres may be detected under imaging such as, for example, radiography or MRI.
The size of the microspheres may vary. In embodiments, the microspheres range from between 0.1 and 1000 μm.
The material of the microspheres may also vary. Exemplary materials of the microspheres include, without limitation, polymer, glass, ceramic. Examples of microspheres are FluoSpheres (manufactured by Thermo Fisher, Eugene, Oreg.).
Examples of therapeutic agents to be delivered by the microspheres include, without limitation, chemotherapy drugs, checkpoint inhibitor, immunotherapy agents, antibiotics or antiseptic agents.
In embodiments, the microspheres release the therapeutic agent over time. In embodiments, the therapeutic agent is heat activated, and treats the tumor.
Optionally, additional energy (e.g., RF ablation) or other treatment and ablation modalities may be applied to the tumor. Preferably, multiple modalities are applied in only one first treatment procedure.
A wide range of energy modalities may be employed in accordance with the present invention. Examples of suitable energy modalities include RF, laser, microwave, cryogenic fluid, resistive heating, ultrasound and other energy delivery mechanisms for heating a target lung volume.
In another embodiment, a method of treating a suspect tissue mass comprises: delivering a heat activated therapeutic agent to the suspect tissue mass; delivering a condensable vapor comprising water to the suspect tissue mass to activate the heat activated therapeutic agent; and delivering energy to heat the suspect tissue mass to destroy the suspect tissue mass from the inside out.
In embodiments, the heat activated therapeutic agent can be delivered systemically and only activated in the suspect tissue mass where the vapor is delivered.
In embodiments, the heat activated therapeutic agent is delivered via a bronchoscopic aerosol.
The agents delivered in the method may vary widely. Examples of heat activated therapeutic agents include, without limitation, a chemotherapy drug, immunotherapy agent, or a checkpoint inhibitor.
Additionally, it is to be understood that the order of the modalities may vary. In embodiments, the vapor ablation may be performed prior to the second modality or vice versa.
The invention has been discussed in terms of certain embodiments. One of skill in the art, however, will recognize that various modifications may be made without departing from the scope of the invention. For example, numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Moreover, while certain features may be shown or discussed in relation to a particular embodiment, such individual features may be used on the various other embodiments of the invention.
This application claims the benefit of provisional patent application No. 62/556,785, filed Sep. 11, 2017, entitled “BRONCHOSCOPIC MULTIMODALITY LUNG TUMOR TREATMENT”, incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
408899 | Small | Aug 1889 | A |
1719750 | Bridge et al. | Jul 1929 | A |
3507283 | Thomas, Jr. | Apr 1970 | A |
3880168 | Berman | Apr 1975 | A |
4026285 | Jackson | May 1977 | A |
4713060 | Riuli | Dec 1987 | A |
4773410 | Blackmer et al. | Sep 1988 | A |
4793352 | Eichenlaub | Dec 1988 | A |
4915113 | Holman | Apr 1990 | A |
4950266 | Sinofsky | Aug 1990 | A |
5006119 | Acker et al. | Apr 1991 | A |
5011566 | Hoffman | Apr 1991 | A |
5084043 | Hertzmann et al. | Jan 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5158536 | Michael et al. | Oct 1992 | A |
5263951 | Spears et al. | Nov 1993 | A |
5331947 | Shturman | Jul 1994 | A |
5334190 | Seiler | Aug 1994 | A |
5348551 | Spears et al. | Sep 1994 | A |
5352512 | Hoffman | Oct 1994 | A |
5424620 | Cheon et al. | Jun 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5503638 | Cooper et al. | Apr 1996 | A |
5524620 | Rosenschein | Jun 1996 | A |
5529076 | Schachar | Jun 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5562608 | Michael et al. | Oct 1996 | A |
5575803 | Cooper et al. | Nov 1996 | A |
5591157 | Hennings et al. | Jan 1997 | A |
5620440 | Heckele et al. | Apr 1997 | A |
5695507 | Auth et al. | Dec 1997 | A |
5735811 | Brisken | Apr 1998 | A |
5752965 | Francis et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5782914 | Schankereli | Jul 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5824703 | Clark, Jr. | Oct 1998 | A |
5827268 | Laufer | Oct 1998 | A |
5913856 | Chia et al. | Jun 1999 | A |
5957919 | Laufer | Sep 1999 | A |
5964752 | Stone | Oct 1999 | A |
5972026 | Laufer et al. | Oct 1999 | A |
5986662 | Argiro et al. | Nov 1999 | A |
5989445 | Wise et al. | Nov 1999 | A |
6032077 | Pomeranz | Feb 2000 | A |
6053909 | Shadduck | Apr 2000 | A |
6059011 | Giolo | May 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6099251 | Lafleur | Aug 2000 | A |
6102037 | Koch | Aug 2000 | A |
6113722 | Hoffman et al. | Sep 2000 | A |
6130671 | Argiro | Oct 2000 | A |
6131570 | Schuster et al. | Oct 2000 | A |
6139571 | Fuller et al. | Oct 2000 | A |
6156036 | Sussman et al. | Dec 2000 | A |
6162232 | Shadduck | Dec 2000 | A |
6179805 | Sussman et al. | Jan 2001 | B1 |
6194066 | Hoffman | Feb 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6210404 | Shadduck | Apr 2001 | B1 |
6219059 | Argiro | Apr 2001 | B1 |
6273907 | Laufer | Aug 2001 | B1 |
6283988 | Laufer et al. | Sep 2001 | B1 |
6299633 | Laufer | Oct 2001 | B1 |
6300150 | Venkatasubramanian | Oct 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6327505 | Medhkour et al. | Dec 2001 | B1 |
6394949 | Crowley et al. | May 2002 | B1 |
6398759 | Sussman et al. | Jun 2002 | B1 |
6398775 | Perkins et al. | Jun 2002 | B1 |
6409723 | Edwards | Jun 2002 | B1 |
6411852 | Danek et al. | Jun 2002 | B1 |
6458231 | Wapner et al. | Oct 2002 | B1 |
6468313 | Claeson et al. | Oct 2002 | B1 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6508816 | Shadduck | Jan 2003 | B2 |
6527761 | Soltesz et al. | Mar 2003 | B1 |
6575929 | Sussman et al. | Jun 2003 | B2 |
6579270 | Sussman et al. | Jun 2003 | B2 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6588613 | Pechenik et al. | Jul 2003 | B1 |
6589201 | Sussman et al. | Jul 2003 | B1 |
6592594 | Rimbaugh et al. | Jul 2003 | B2 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6610043 | Ingenito | Aug 2003 | B1 |
6629951 | Laufer et al. | Oct 2003 | B2 |
6652594 | Francis et al. | Nov 2003 | B2 |
6653525 | Ingenito et al. | Nov 2003 | B2 |
6669694 | Shadduck | Dec 2003 | B2 |
6676628 | Sussman et al. | Jan 2004 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6682520 | Ingenito | Jan 2004 | B2 |
6692494 | Cooper et al. | Feb 2004 | B1 |
6712812 | Roschak et al. | Mar 2004 | B2 |
6719738 | Mehier | Apr 2004 | B2 |
6755794 | Soukup | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6776765 | Soukup et al. | Aug 2004 | B2 |
6860847 | Alferness et al. | Mar 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6901927 | Deem et al. | Jun 2005 | B2 |
6904909 | Deem et al. | Jun 2005 | B2 |
6907881 | Suki et al. | Jun 2005 | B2 |
6911028 | Shadduck | Jun 2005 | B2 |
6986769 | Nelson et al. | Jan 2006 | B2 |
6997189 | Biggs et al. | Feb 2006 | B2 |
7022088 | Keast et al. | Apr 2006 | B2 |
7027869 | Danek et al. | Apr 2006 | B2 |
7031504 | Argiro et al. | Apr 2006 | B1 |
7083612 | Littrup et al. | Aug 2006 | B2 |
7128748 | Mooradian et al. | Oct 2006 | B2 |
7136064 | Zuiderveld | Nov 2006 | B2 |
7144402 | Kuester et al. | Dec 2006 | B2 |
7144588 | Nicholas et al. | Dec 2006 | B2 |
7174644 | Critelli et al. | Feb 2007 | B2 |
7175644 | Cooper et al. | Feb 2007 | B2 |
7192400 | Campbell et al. | Mar 2007 | B2 |
7198635 | Danaek et al. | Apr 2007 | B2 |
7233820 | Gilboa | Jun 2007 | B2 |
7235070 | Vanney | Jun 2007 | B2 |
7335195 | Mehier | Feb 2008 | B2 |
7347859 | Garabedian et al. | Mar 2008 | B2 |
7412977 | Fields et al. | Aug 2008 | B2 |
7422563 | Roschak et al. | Sep 2008 | B2 |
7422584 | Loomas et al. | Sep 2008 | B2 |
7425212 | Danek et al. | Sep 2008 | B1 |
7462162 | Phan et al. | Dec 2008 | B2 |
7628789 | Soltesz et al. | Dec 2009 | B2 |
7708712 | Phan et al. | May 2010 | B2 |
7740017 | Danek et al. | Jun 2010 | B2 |
7756563 | Higgins et al. | Jul 2010 | B2 |
7778704 | Rezai et al. | Aug 2010 | B2 |
7815590 | Cooper | Oct 2010 | B2 |
7819908 | Ingenito | Oct 2010 | B2 |
7889905 | Higgins et al. | Feb 2011 | B2 |
7906124 | Laufer et al. | Mar 2011 | B2 |
7913698 | Barry et al. | Mar 2011 | B2 |
7985187 | Wibowo et al. | Jul 2011 | B2 |
7993323 | Barry et al. | Aug 2011 | B2 |
8002740 | Willink et al. | Aug 2011 | B2 |
8088127 | Mayse et al. | Jan 2012 | B2 |
8147532 | Barry et al. | Apr 2012 | B2 |
8172827 | Deem et al. | May 2012 | B2 |
8187269 | Shadduck et al. | May 2012 | B2 |
8251070 | Danek et al. | Aug 2012 | B2 |
8292882 | Danek et al. | Oct 2012 | B2 |
8322335 | Barry et al. | Dec 2012 | B2 |
8409167 | Roschak | Apr 2013 | B2 |
8444636 | Shadduck et al. | May 2013 | B2 |
8585645 | Barry et al. | Nov 2013 | B2 |
8608724 | Roschak | Dec 2013 | B2 |
8628495 | Horton et al. | Jan 2014 | B2 |
8709034 | Keast et al. | Apr 2014 | B2 |
8734380 | Barry et al. | May 2014 | B2 |
8784400 | Roschak | Jul 2014 | B2 |
8858549 | Shadduck et al. | Oct 2014 | B2 |
8900223 | Shadduck | Dec 2014 | B2 |
9037215 | Higgins et al. | May 2015 | B2 |
9050076 | Barry et al. | Jun 2015 | B2 |
9133858 | Macchia et al. | Sep 2015 | B2 |
9265468 | Rai et al. | Feb 2016 | B2 |
9393396 | Peyman | Jul 2016 | B2 |
9913969 | Roschak | Mar 2018 | B2 |
10064697 | Sharma et al. | Sep 2018 | B2 |
20020077516 | Flanigan | Jun 2002 | A1 |
20020111386 | Michael et al. | Aug 2002 | A1 |
20020112723 | Schuster et al. | Aug 2002 | A1 |
20020177846 | Mulier | Nov 2002 | A1 |
20030055331 | Kotmel et al. | Mar 2003 | A1 |
20030099279 | Venkatasubramanian et al. | May 2003 | A1 |
20030139789 | Tvinnereim | Jul 2003 | A1 |
20030181922 | Alferness | Sep 2003 | A1 |
20030233099 | Danaek et al. | Dec 2003 | A1 |
20040031494 | Danek et al. | Feb 2004 | A1 |
20040038868 | Ingenito | Feb 2004 | A1 |
20040047855 | Ingenito | Mar 2004 | A1 |
20040055606 | Hendricksen et al. | Mar 2004 | A1 |
20040068306 | Shadduck | Apr 2004 | A1 |
20040131587 | Thomas et al. | Jul 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040200484 | Springmeyer | Oct 2004 | A1 |
20040244803 | Tanaka | Dec 2004 | A1 |
20050016530 | McCutcheon | Jan 2005 | A1 |
20050066974 | Fields et al. | Mar 2005 | A1 |
20050166925 | Wilson et al. | Aug 2005 | A1 |
20050171396 | Pankratov et al. | Aug 2005 | A1 |
20050171582 | Matlock | Aug 2005 | A1 |
20050203483 | Perkins et al. | Sep 2005 | A1 |
20050215991 | Altman et al. | Sep 2005 | A1 |
20050222485 | Shaw et al. | Oct 2005 | A1 |
20060004400 | Mcgurk et al. | Jan 2006 | A1 |
20060047291 | Barry | Mar 2006 | A1 |
20060100619 | Mcclurken et al. | May 2006 | A1 |
20060130830 | Barry | Jun 2006 | A1 |
20060135955 | Shadduck | Jun 2006 | A1 |
20060161233 | Barry | Jul 2006 | A1 |
20060162731 | Wondka et al. | Jul 2006 | A1 |
20060200076 | Gonzalez et al. | Sep 2006 | A1 |
20060224154 | Shadduck et al. | Oct 2006 | A1 |
20070032785 | Diederich et al. | Feb 2007 | A1 |
20070036417 | Argiro et al. | Feb 2007 | A1 |
20070068530 | Pacey | Mar 2007 | A1 |
20070091087 | Zuiderveld | Apr 2007 | A1 |
20070092864 | Reinhardt et al. | Apr 2007 | A1 |
20070102011 | Danek et al. | May 2007 | A1 |
20070106292 | Kaplan et al. | May 2007 | A1 |
20070109299 | Peterson | May 2007 | A1 |
20070112349 | Danek et al. | May 2007 | A1 |
20070118184 | Danek et al. | May 2007 | A1 |
20070137646 | Weinstein et al. | Jun 2007 | A1 |
20070293853 | Truckai et al. | Dec 2007 | A1 |
20080033493 | Deckman et al. | Feb 2008 | A1 |
20080132826 | Shadduck et al. | Jun 2008 | A1 |
20090018538 | Webster et al. | Jan 2009 | A1 |
20090043301 | Jarrard et al. | Feb 2009 | A1 |
20090118538 | Pizzocaro et al. | May 2009 | A1 |
20090138001 | Barry et al. | May 2009 | A1 |
20090149846 | Hoey et al. | Jun 2009 | A1 |
20090149897 | Dacey, Jr. et al. | Jun 2009 | A1 |
20090156895 | Higgins et al. | Jun 2009 | A1 |
20090192508 | Laufer et al. | Jul 2009 | A1 |
20090216220 | Hoey et al. | Aug 2009 | A1 |
20090301483 | Barry et al. | Dec 2009 | A1 |
20090306640 | Glaze et al. | Dec 2009 | A1 |
20090306644 | Mayse et al. | Dec 2009 | A1 |
20090312753 | Shadduck | Dec 2009 | A1 |
20100094270 | Sharma | Apr 2010 | A1 |
20100185087 | Nields | Jul 2010 | A1 |
20100204688 | Hoey | Aug 2010 | A1 |
20100256714 | Springmeyer | Oct 2010 | A1 |
20100262133 | Hoey et al. | Oct 2010 | A1 |
20100310146 | Higgins et al. | Dec 2010 | A1 |
20110077628 | Hoey et al. | Mar 2011 | A1 |
20110118725 | Mayse et al. | May 2011 | A1 |
20110160648 | Hoey | Jun 2011 | A1 |
20110172654 | Barry et al. | Jul 2011 | A1 |
20110257644 | Barry et al. | Oct 2011 | A1 |
20110270031 | Frazier et al. | Nov 2011 | A1 |
20110301587 | Deem et al. | Dec 2011 | A1 |
20120016363 | Mayse et al. | Jan 2012 | A1 |
20120016364 | Mayse et al. | Jan 2012 | A1 |
20120289776 | Keast et al. | Nov 2012 | A1 |
20130006231 | Sharma | Jan 2013 | A1 |
20130267939 | Barry et al. | Oct 2013 | A1 |
20130324987 | Leung et al. | Dec 2013 | A1 |
20140025057 | Hoey et al. | Jan 2014 | A1 |
20140088669 | Lanphere | Mar 2014 | A1 |
20140163664 | Goldsmith | Jun 2014 | A1 |
20140275952 | Monroe et al. | Sep 2014 | A1 |
20140276713 | Hoey et al. | Sep 2014 | A1 |
20150094607 | Barry et al. | Apr 2015 | A1 |
20150230852 | Barry et al. | Aug 2015 | A1 |
20160008050 | Rajagopalan | Jan 2016 | A1 |
20160180529 | Rai et al. | Jun 2016 | A1 |
20160220297 | Kroon et al. | Aug 2016 | A1 |
20160310200 | Wang | Oct 2016 | A1 |
20170172640 | Henne | Jun 2017 | A1 |
20180055495 | Tehrani | Mar 2018 | A1 |
20180318002 | Barry et al. | Nov 2018 | A1 |
20190069948 | Herth et al. | Mar 2019 | A1 |
20190343579 | Tandri et al. | Nov 2019 | A1 |
Number | Date | Country |
---|---|---|
721086 | Jun 2000 | AU |
1003582 | Feb 2003 | EP |
1143864 | Feb 2004 | EP |
1173103 | Oct 2005 | EP |
1326549 | Dec 2005 | EP |
1326548 | Jan 2006 | EP |
1485033 | Aug 2009 | EP |
0011927 | Mar 2000 | WO |
0102042 | Jan 2001 | WO |
02069821 | Sep 2002 | WO |
03070302 | Aug 2003 | WO |
03086498 | Oct 2003 | WO |
2005025635 | Mar 2005 | WO |
2005102175 | Nov 2005 | WO |
2006003665 | Jan 2006 | WO |
2006052940 | May 2006 | WO |
2006053308 | May 2006 | WO |
2006053309 | May 2006 | WO |
2006080015 | Aug 2006 | WO |
2006116198 | Nov 2006 | WO |
2008051706 | May 2008 | WO |
WO-2008064026 | May 2008 | WO |
2009009236 | Jan 2009 | WO |
2009009398 | Jan 2009 | WO |
2009015278 | Jan 2009 | WO |
WO-2009009398 | Jan 2009 | WO |
2009137819 | Nov 2009 | WO |
2010042461 | Apr 2010 | WO |
2011056684 | May 2011 | WO |
2011060200 | May 2011 | WO |
2011060201 | May 2011 | WO |
2011127216 | Oct 2011 | WO |
Entry |
---|
Becker, et al.; Lung volumes before and after lung volume reduction surgery; Am J Respir Crit Care Med; vol. 157; pp. 1593-1599; (1998) Oct. 28, 1997. |
Blacker, G. F.; Vaporization of the uterus; J. of Obstetrics and Gynaecology; vol. 33; pp. 488-511; 1902. |
Carpenter III et al.; Comparison of endoscopic cryosurgery and electrocoagulation of bronchi; Trans. Amer. Acad. Opth.; vol. 84; No. 1; pp. ORL-313-ORL-323; Jan. 1977. |
clinical trials.gov.; Study of the AeriSeal System for Hyperinflation Reduction in Emphysema; 4 pages; Nov. 5, 2014; retrieved from the internet (http://clinicaltrials.gov/show/NCT01449292). |
Coda, et al., “Effects of pulmonary reventilation on gas exchange after cryolytic disobstruction of endobronchial tumors,” Minerva Medical, vol. 72, pp. 1627-1631, Jun. 1981 (w/ Eng. Trans.). |
Cox et al., “Bronchial Thermoplasty for Asthma.” American Journal of Respiratory Critical Care Medicine 173: 965-969 (2006). |
Delaunois; Anatomy and physiology of collateral respiratory pathways; Eur. Respir. J.; 2(9); pp. 893-904; Oct. 1989. |
Eyal et al.; The acute effect of pulmonary burns on lung mechanics and gas exchange in the rabbit; Br. J. Anaesth.; vol. 47; pp. 546-552; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1975. |
Ferlay et al.; GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [internet]; 16 pages; retrieved from the Internet (http://www.iarc.fr/en/media-centre/iarcnews/2010/GLOBOCAN2008.pdf); Lyon, France: International Agency for Research on Cancer; Jun. 1, 2010. |
Fishman et al., A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med, vol. 348, No. 21, pp. 2059-2073, May 22, 2003. |
Goldberg et al.; Radiofrequency tissue ablation in the rabbit lung: Efficacy and complications; Acad. Radiol.; vol. 2; pp. 776-784; Sep. 1995. |
Henne et al.; U.S. Appl. No. 14/957,433 entitled “Vapor treatment of lung nodules and tumors,” filed Dec. 2, 2015. |
Herth et al.; Efficacy predictors of lung volume reduction with zephyr valves in a european cohort; Eur. Respir. J.; 39(6); pp. 1334-1342; Jun. 2012. |
Homasson, et al., “Bronchoscopic cryotherapy for airway strictures caused by tumors,” Chest, vol. 90, No. 2, pp. 159-164, Aug. 1986. |
Kang, Li, “Efficient optimal net surface detection for image segmentation—from theory to practice,” M.Sc. Thesis, The University of Iowa, Dec. 2003. |
Kinsella et al.; Quantitation of emphysema by computed tomography using a “densitymask” program and correlation with pulmonary function tests; Chest; 97(2); pp. 315-321; Feb. 1990. |
Looga, R. U.; Mechanism of changes in the respiratory and cardiovascular reflexes from the lungs associated with intrapulmonary steam burns; Eng. Trans. from Byulleten Eksperimental noi Biologii I Meditsiny; vol. 61; No. 6; pp. 31-33; Jun. 1966. |
Marasso, et al., “Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis,” Chest, vol. 103, No. 2, pp. 472-474, Feb. 1993. |
Marasso, et al., “Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique,” Thorax, vol. 53, pp. 106-109, (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1998. |
Mathur et al., Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction, Chest, vol. 110, No. 3, pp. 718-723, Sep. 1996. |
Morice et al.; Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction, Chest, vol. 119, No. 3, pp. 781-787, Mar. 2001. |
Moritz et al.; The effects of inhaled heat on the air pasage and lungs; American Journal of Pathology; vol. XXI; pp. 311-331; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1944. |
Moulding et al.; Preliminary studies for achieving transcervical oviduct occlusion by hot water or low-pressure steam; Advances in Planned Parenthood; vol. 12, No. 2; pp. 79-85; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1977. |
National Lung Screening Trial Research Team; Reduced lung-cancer mortality with low-dose computed tomographic screening; N. Eng. J. Med.; 365(5); pp. 395-409; Aug. 4, 2011. |
Pieter et al.; U.S. Appl. No. 15/013,748 entitled “Medical vapor generator,” filed Feb. 2, 2016. |
Pracht, Adam, “VIDA takes new approach,” Iowa City Press-Citizen, Sep. 12, 2005. |
Quin, Jacquelyn, “Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, pp. 407-412, Jul. 1995. |
Sciurba et al.; A randomized study of endobronchial valves for advanced emphysema; N. Eng. J. Med.; 363(13); pp. 1233-1244; Sep. 23, 2010. |
Shah et al.; Collateral ventilation and selection of techniques for bronchoscopic lung volume reduction; Thorax; 67(4); pp. 285-286; Apr. 2012. |
Slebos et al.; Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema; Chest; 142(3); pp. 574-582; Sep. 2012. |
Sutedja, et al.; Bronchoscopic treatment of lung tumors; Elsevier, Lung Cancer, 11, pp. 1-17, Jul. 1994. |
Tschirren et al.; Intrathoracic airway trees: segmentation and airway morphology analysis from low-dose CT scans; IEEE Trans. Med. Imaging; vol. 24, No. 12; pp. 1529-1539; Dec. 2005. |
Tschirren, Juerg; Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images; Ph.D. Thesis; The University of Iowa; Aug. 2003. |
Tschirren, Juerg; Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images; Slides from Ph.D. defense; The University of Iowa; Jul. 10, 2003. |
Van De Velde; Vapo-cauterization of the uterus; Amer. J. Med. Sci.; vol. CXVIII; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1899. |
Vorre et al.; Morphology of tracheal scar after resection with CO2-laser and high-frequency cutting loop; Acta Otolaryngol (Stockh); vol. 107; pp. 307-312; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1989. |
Number | Date | Country | |
---|---|---|---|
20190076189 A1 | Mar 2019 | US |
Number | Date | Country | |
---|---|---|---|
62556785 | Sep 2017 | US |